Cargando…

Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial: the protocol for a large pilot study

INTRODUCTION: Acute kidney injury (AKI) contributes to morbidity and mortality, and its care is often suboptimal and/or delayed. The Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) study is a large pilot testing provision of early specialist advice, to improve outcomes for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelaziz, Tarek Samy, Lindenmeyer, Antje, Baharani, Jyoti, Mistry, Hema, Sitch, Alice, Temple, R Mark, Perkins, Gavin, Thomas, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013506/
https://www.ncbi.nlm.nih.gov/pubmed/27543592
http://dx.doi.org/10.1136/bmjopen-2016-012253
_version_ 1782452180044742656
author Abdelaziz, Tarek Samy
Lindenmeyer, Antje
Baharani, Jyoti
Mistry, Hema
Sitch, Alice
Temple, R Mark
Perkins, Gavin
Thomas, Mark
author_facet Abdelaziz, Tarek Samy
Lindenmeyer, Antje
Baharani, Jyoti
Mistry, Hema
Sitch, Alice
Temple, R Mark
Perkins, Gavin
Thomas, Mark
author_sort Abdelaziz, Tarek Samy
collection PubMed
description INTRODUCTION: Acute kidney injury (AKI) contributes to morbidity and mortality, and its care is often suboptimal and/or delayed. The Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) study is a large pilot testing provision of early specialist advice, to improve outcomes for patients with AKI. METHODS AND ANALYSIS: This before and after study will test an Outreach service for adult patients with AKI, identified using the national algorithm. During the 2-month before phase, AKI outcomes (30-day mortality, need for dialysis or AKI stage deterioration) will be observed in the intervention and control hospitals and their respective community areas; no interventions will be delivered. Patients will receive good standard care. During the 5-month after phase, the intervention will be delivered to patients with AKI in the intervention hospital and its area. Patients with AKI in the control hospital and its area will continue to have good standard care only. Patients already on dialysis and at end of life will be excluded. The interventions will be initially delivered via a phone call, with or without a visit to the primary clinician, aiming at rapidly establishing the aetiology, correcting reversible causes and conducting further appropriate investigation. Surviving stage 3 patients will be followed-up in an AKI clinic. We will conduct qualitative research using focus group-based discussions with primary and secondary care clinicians during the early and late phases of the trial. This will help break down potential barriers and improve care delivery. ETHICS AND DISSEMINATION: Patients will be contacted about the study allowing them to ‘opt out’. The work of an Outreach team, guided by AKI alerts and delivering timely advice to clinicians, may improve outcomes. If the results suggest that benefits are delivered by an AKI Outreach team, this study will lead to a full cluster randomised trial. TRIAL REGISTRATION NUMBER: NCT02398682: Pre-results.
format Online
Article
Text
id pubmed-5013506
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-50135062016-09-12 Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial: the protocol for a large pilot study Abdelaziz, Tarek Samy Lindenmeyer, Antje Baharani, Jyoti Mistry, Hema Sitch, Alice Temple, R Mark Perkins, Gavin Thomas, Mark BMJ Open Renal Medicine INTRODUCTION: Acute kidney injury (AKI) contributes to morbidity and mortality, and its care is often suboptimal and/or delayed. The Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) study is a large pilot testing provision of early specialist advice, to improve outcomes for patients with AKI. METHODS AND ANALYSIS: This before and after study will test an Outreach service for adult patients with AKI, identified using the national algorithm. During the 2-month before phase, AKI outcomes (30-day mortality, need for dialysis or AKI stage deterioration) will be observed in the intervention and control hospitals and their respective community areas; no interventions will be delivered. Patients will receive good standard care. During the 5-month after phase, the intervention will be delivered to patients with AKI in the intervention hospital and its area. Patients with AKI in the control hospital and its area will continue to have good standard care only. Patients already on dialysis and at end of life will be excluded. The interventions will be initially delivered via a phone call, with or without a visit to the primary clinician, aiming at rapidly establishing the aetiology, correcting reversible causes and conducting further appropriate investigation. Surviving stage 3 patients will be followed-up in an AKI clinic. We will conduct qualitative research using focus group-based discussions with primary and secondary care clinicians during the early and late phases of the trial. This will help break down potential barriers and improve care delivery. ETHICS AND DISSEMINATION: Patients will be contacted about the study allowing them to ‘opt out’. The work of an Outreach team, guided by AKI alerts and delivering timely advice to clinicians, may improve outcomes. If the results suggest that benefits are delivered by an AKI Outreach team, this study will lead to a full cluster randomised trial. TRIAL REGISTRATION NUMBER: NCT02398682: Pre-results. BMJ Publishing Group 2016-08-19 /pmc/articles/PMC5013506/ /pubmed/27543592 http://dx.doi.org/10.1136/bmjopen-2016-012253 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Renal Medicine
Abdelaziz, Tarek Samy
Lindenmeyer, Antje
Baharani, Jyoti
Mistry, Hema
Sitch, Alice
Temple, R Mark
Perkins, Gavin
Thomas, Mark
Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial: the protocol for a large pilot study
title Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial: the protocol for a large pilot study
title_full Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial: the protocol for a large pilot study
title_fullStr Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial: the protocol for a large pilot study
title_full_unstemmed Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial: the protocol for a large pilot study
title_short Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) trial: the protocol for a large pilot study
title_sort acute kidney outreach to reduce deterioration and death (akordd) trial: the protocol for a large pilot study
topic Renal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013506/
https://www.ncbi.nlm.nih.gov/pubmed/27543592
http://dx.doi.org/10.1136/bmjopen-2016-012253
work_keys_str_mv AT abdelaziztareksamy acutekidneyoutreachtoreducedeteriorationanddeathakorddtrialtheprotocolforalargepilotstudy
AT lindenmeyerantje acutekidneyoutreachtoreducedeteriorationanddeathakorddtrialtheprotocolforalargepilotstudy
AT baharanijyoti acutekidneyoutreachtoreducedeteriorationanddeathakorddtrialtheprotocolforalargepilotstudy
AT mistryhema acutekidneyoutreachtoreducedeteriorationanddeathakorddtrialtheprotocolforalargepilotstudy
AT sitchalice acutekidneyoutreachtoreducedeteriorationanddeathakorddtrialtheprotocolforalargepilotstudy
AT templermark acutekidneyoutreachtoreducedeteriorationanddeathakorddtrialtheprotocolforalargepilotstudy
AT perkinsgavin acutekidneyoutreachtoreducedeteriorationanddeathakorddtrialtheprotocolforalargepilotstudy
AT thomasmark acutekidneyoutreachtoreducedeteriorationanddeathakorddtrialtheprotocolforalargepilotstudy